Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. trimmed its position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 6.6% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 433,359 shares of the company’s stock after selling 30,668 shares during the period. JPMorgan Chase & Co. owned approximately 0.48% of Caribou Biosciences worth $849,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of CRBU. Barclays PLC increased its stake in Caribou Biosciences by 122.4% during the third quarter. Barclays PLC now owns 129,839 shares of the company’s stock worth $255,000 after purchasing an additional 71,463 shares during the period. Geode Capital Management LLC grew its holdings in shares of Caribou Biosciences by 6.5% in the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after purchasing an additional 124,782 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in Caribou Biosciences during the 3rd quarter worth approximately $28,000. PFM Health Sciences LP increased its stake in Caribou Biosciences by 5.5% during the 3rd quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock worth $8,441,000 after buying an additional 223,299 shares during the period. Finally, Walleye Capital LLC lifted its holdings in Caribou Biosciences by 45.9% during the 3rd quarter. Walleye Capital LLC now owns 237,599 shares of the company’s stock worth $466,000 after buying an additional 74,799 shares in the last quarter. 77.51% of the stock is currently owned by hedge funds and other institutional investors.

Caribou Biosciences Trading Down 0.7 %

Shares of CRBU stock opened at $1.51 on Friday. The stock has a 50 day simple moving average of $1.83 and a 200-day simple moving average of $2.00. The company has a market cap of $136.73 million, a price-to-earnings ratio of -0.92 and a beta of 2.34. Caribou Biosciences, Inc. has a 12-month low of $1.47 and a 12-month high of $8.33.

Caribou Biosciences (NASDAQ:CRBU) last released its earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. The company had revenue of $2.02 million during the quarter, compared to the consensus estimate of $3.37 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. On average, equities analysts forecast that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CRBU has been the topic of a number of recent research reports. Bank of America cut their price objective on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Citigroup cut their price target on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Caribou Biosciences in a research note on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $10.33.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.